








Highlights from the

National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs

Who Participated in the Study? MUSC What Types of **Navigators Were** Represented? **Patient 57 FTEs** Clinical 37% Social 59% Worker (34)4% (2) 77% **/// /// Navigator Educational Profiles** 13% 11%
















Does Navigator Education, Tenure and Certification Matter?





FINDING: Potential relationship between education level and metric performance




--

FINDING: Longer tenure in oncology renders higher levels of identification of learning style, support referrals and barriers to care













Caseloads and FTE Statistics

4,462Nov 2018 – Apr 2019




New Patients


50% of Tumor Registry Analytic Cases Were Navigated




Average Cases per Navigator
















Readmissions Rates

Percentage Caseloads by Stage of Disease






Readmission Rates lower than baseline during the study period

30-Day 60-Day 90-Day BASELINE 10.8% 15.5% 17.9% STUDY STUDY STUDY 9.8% 14.3% 16.3%



- Staging mix comparable to pre-study period
- Disease complexity did not account for higher readmission rates for navigated patients












Barriers to Care

≈90% practical, emotional or physical

2.2 per patient (lower than baseline of 2.4)

Distribution of Barriers



Top Reported Barriers







Transportation





Nervousness







Income





Treatment Decisions




Fear of Tx/ Side Effects



FINDING


Higher percentage of barriers associated with more complex cases






FINDING

Modest relationship between barrier count and distress score.












How Much Time from Diagnosis to Treatment?






Navigated patients experienced shorter time between diagnosis and treatment.


1 days less



Average Days to Treatment by Disease¹



Average Days to Treatment by Barrier Count





Specific Barriers May Attribute to Delays to Treatment²



Financial



Emotional



47 Days (59 patients)

Practical



56 Days (223 patients)

Physical



33 Days (51 patients)

Family




23 Days (9 patients)

No Barriers



31 Days (40 patients)











DISTRESS SCREENING


42% Patients Screened


Total Patients 1,987

How Many Patients Were Screened by Facility?
















993 (54%)


SOCIAL Support Referrals


Average Referrals by Patient




Support Referrals by Type


















PALLIATIVE Referrals

Palliative Care Referrals by Facility and Average Referrals per Patient



Facility	# Palliative Referrals	# Patients Navigated	Percentage Referred
1	326	481	68%
2	35	238	15%
3	200	468	43%
4	40	1,114	4%
5	36	697	5%
6	11	488	2%
7	0	921	0%
8	39	275	14%
Total	687	4,682	15%

Average Palliative Care Referrals per Patient by Disease Site











LEARNING STYLES

Percentage Distribution of Learning Style











VERBAL

SOCIAL


PHYSICAL

44%


10% 5%

9%

Average Number of Identified Learning Styles per Patient by Disease



PATICALAS SHIP ON COLON THER THER STATE BREAST HOW BLOOD GAN RECTAL



A Little

Not at All

n = 204

31

50








Yes, Somewhat

■ No

142

n=209


Page 11



Q3
Since diagnosis, did a navigator ask your goals for treatment?

74%

100




In the last 3 months, how often did a navigator listen to your needs?

150 135 82%

100 27 23 12

0 Always Usually Sometimes Never















PATIENT SURVEYS

(Continued)


Q5




Q6



Q7





Acknowledgement: A very special thank you to Merck Foundation for partial funding for this study.



Ownership of Copyright

Materials published in *Journal of Oncology Navigation & Survivorship* (JONS) and by the National Metrics Study Investigational Team are owned and copyrighted by Green Hill Healthcare Communications (GHHC). Materials under GHHC copyright remain the property of GHHC and may not be reproduced without permission from the publisher.

ONC iQ copyright by Chartis Oncology Solutions